- Home
- BBIO vs KNX Comparison
BBIO vs KNX Comparison
Compare BBIO & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- KNX
- Stock Information
- Founded
- BBIO 2015
- KNX 1989
- Country
- BBIO United States
- KNX United States
- Employees
- BBIO N/A
- KNX N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- KNX Trucking Freight/Courier Services
- Sector
- BBIO Health Care
- KNX Industrials
- Exchange
- BBIO Nasdaq
- KNX Nasdaq
- Market Cap
- BBIO 8.8B
- KNX 7.3B
- IPO Year
- BBIO 2019
- KNX 1994
- Fundamental
- Price
- BBIO $49.08
- KNX $44.96
- Analyst Decision
- BBIO Strong Buy
- KNX Buy
- Analyst Count
- BBIO 16
- KNX 16
- Target Price
- BBIO $61.69
- KNX $54.69
- AVG Volume (30 Days)
- BBIO 2.9M
- KNX 2.8M
- Earning Date
- BBIO 08-05-2025
- KNX 10-22-2025
- Dividend Yield
- BBIO N/A
- KNX 1.69%
- EPS Growth
- BBIO N/A
- KNX 148.62
- EPS
- BBIO N/A
- KNX 1.02
- Revenue
- BBIO $235,812,000.00
- KNX $7,427,259,000.00
- Revenue This Year
- BBIO $106.33
- KNX $2.43
- Revenue Next Year
- BBIO $54.30
- KNX $6.65
- P/E Ratio
- BBIO N/A
- KNX $44.18
- Revenue Growth
- BBIO 7.62
- KNX N/A
- 52 Week Low
- BBIO $21.72
- KNX $36.69
- 52 Week High
- BBIO $51.86
- KNX $61.51
- Technical
- Relative Strength Index (RSI)
- BBIO 55.76
- KNX 57.22
- Support Level
- BBIO $48.03
- KNX $41.49
- Resistance Level
- BBIO $51.86
- KNX $43.94
- Average True Range (ATR)
- BBIO 1.95
- KNX 1.27
- MACD
- BBIO -0.08
- KNX 0.27
- Stochastic Oscillator
- BBIO 71.55
- KNX 86.99
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About KNX Knight-Swift Transportation Holdings Inc.
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.